| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.874 | 0.004 | 0.874 | Spasmolytic | 0.815 0.004 DBMET00391 | ||
| 0.786 | 0.005 | 0.841 | Toll-Like receptor 7 agonist | 0.841 0.005 DBMET00391 | DBMET00391 | |
| 0.782 | 0.005 | 0.839 | Toll-Like receptor agonist | 0.839 0.005 DBMET00391 | DBMET00391 | |
| 0.686 | 0.003 | 0.795 | Histamine H1 receptor antagonist | 0.795 0.003 DBMET00391 | DBMET00391 | |
| 0.67 | 0.003 | 0.67 | Acetylcholine muscarinic antagonist | 0.548 0.004 DBMET00391 | ||
| 0.652 | 0.005 | 0.652 | HERG channel blocker | 0.578 0.009 DBMET00391 | ||
| 0.647 | 0.004 | 0.647 | Cholinergic antagonist | 0.515 0.005 DBMET00391 | ||
| 0.645 | 0.004 | 0.645 | Acetylcholine antagonist | 0.508 0.005 DBMET00391 | ||
| 0.636 | 0.005 | 0.636 | Potassium channel (Voltage-sensitive) blocker | 0.56 0.009 DBMET00391 | ||
| 0.632 | 0.003 | 0.632 | Acetylcholine M1 receptor antagonist | 0.488 0.004 DBMET00391 | ||
| 0.621 | 0.005 | 0.621 | Potassium channel blocker | 0.549 0.008 DBMET00391 | ||
| 0.577 | 0.004 | 0.611 | Antihistaminic | 0.611 0.004 DBMET00391 | DBMET00391 | |
| 0.57 | 0.004 | 0.57 | Interleukin 4 antagonist | 0.452 0.005 DBMET00391 | ||
| 0.538 | 0.004 | 0.566 | Histamine antagonist | 0.566 0.004 DBMET00391 | DBMET00391 | |
| 0.514 | 0.002 | 0.514 | Acetylcholine M3 receptor antagonist | 0.415 0.003 DBMET00391 | ||
| 0.45 | 0.004 | 0.45 | Alpha 2c adrenoreceptor antagonist | 0.192 0.02 DBMET00391 | ||
| 0.446 | 0.012 | 0.457 | P-glycoprotein inhibitor | 0.457 0.011 DBMET00391 | DBMET00391 | |
| 0.414 | 0.003 | 0.414 | Sphingomyelinase inhibitor | 0.262 0.004 DBMET00391 | ||
| 0.409 | 0.004 | 0.409 | Interleukin 5 antagonist | 0.334 0.004 DBMET00391 | ||
| 0.402 | 0.005 | 0.402 | Bronchodilator | 0.384 0.006 DBMET00391 | ||
| 0.447 | 0.052 | 0.447 | Calcium channel L-type activator | 0.424 0.066 DBMET00391 | ||
| 0.434 | 0.045 | 0.434 | Vasodilator, peripheral | 0.364 0.068 DBMET00391 | ||
| 0.384 | 0.005 | 0.384 | Calcium channel blocker | 0.341 0.007 DBMET00391 | ||
| 0.373 | 0.004 | 0.373 | Electron transport complex I inhibitor | 0.218 0.007 DBMET00391 | ||
| 0.371 | 0.004 | 0.371 | Acetylcholine M2 receptor antagonist | 0.208 0.006 DBMET00391 | ||
| 0.366 | 0.008 | 0.493 | Antipruritic | 0.493 0.005 DBMET00391 | DBMET00391 | |
| 0.351 | 0.013 | 0.351 | 5 Hydroxytryptamine 2 antagonist | 0.125 0.055 DBMET00391 | ||
| 0.398 | 0.064 | 0.474 | Immunosuppressant | 0.474 0.04 DBMET00391 | DBMET00391 | |
| 0.371 | 0.038 | 0.371 | Hypoxia-inducible factor 1 alpha inhibitor | 0.26 0.092 DBMET00391 | ||
| 0.33 | 0.005 | 0.33 | Alpha 1d adrenoreceptor antagonist | 0.108 0.021 DBMET00391 | ||
| 0.328 | 0.003 | 0.328 | Acetylcholine M5 receptor antagonist | 0.201 0.005 DBMET00391 | ||
| 0.318 | 0.004 | 0.318 | Alpha 1 adrenoreceptor agonist | 0.288 0.005 DBMET00391 | ||
| 0.365 | 0.059 | 0.365 | Cholesterol antagonist | 0.324 0.077 DBMET00391 | ||
| 0.316 | 0.013 | 0.316 | Neuropeptide Y2 antagonist | 0.286 0.027 DBMET00391 | ||
| 0.305 | 0.007 | 0.305 | Alpha 1b adrenoreceptor antagonist | 0.122 0.029 DBMET00391 | ||
| 0.306 | 0.014 | 0.306 | 5 Hydroxytryptamine 2B antagonist | 0.118 0.063 DBMET00391 | ||
| 0.29 | 0.012 | 0.29 | 5 Hydroxytryptamine 2A antagonist | 0.096 0.049 DBMET00391 | ||
| 0.283 | 0.005 | 0.283 | Calcium antagonist | 0.241 0.009 DBMET00391 | ||
| 0.252 | 0.004 | 0.252 | Adrenaline agonist | 0.232 0.005 DBMET00391 | ||
| 0.294 | 0.05 | 0.375 | Hypolipemic | 0.375 0.03 DBMET00391 | DBMET00391 | |
| 0.26 | 0.018 | 0.26 | Anesthetic local | 0.192 0.034 DBMET00391 | ||
| 0.244 | 0.004 | 0.244 | Calcium channel L-type blocker | 0.192 0.006 DBMET00391 | ||
| 0.245 | 0.008 | 0.245 | Dopamine D1 antagonist | 0.087 0.03 DBMET00391 | ||
| 0.234 | 0.019 | 0.234 | Antiadrenergic | 0.115 0.048 DBMET00391 | ||
| 0.266 | 0.053 | 0.266 | Psychostimulant | 0.247 0.06 DBMET00391 | ||
| 0.231 | 0.019 | 0.231 | Adrenaline antagonist | 0.112 0.047 DBMET00391 | ||
| 0.232 | 0.031 | 0.232 | Lipid peroxidase inhibitor | 0.156 0.065 DBMET00391 | ||
| 0.204 | 0.008 | 0.204 | Alpha adrenoreceptor agonist | 0.183 0.01 DBMET00391 | ||
| 0.2 | 0.006 | 0.2 | Dopamine uptake inhibitor | 0.106 0.017 DBMET00391 | ||
| 0.202 | 0.009 | 0.202 | Sigma receptor antagonist | 0.079 0.021 DBMET00391 | ||
| 0.207 | 0.014 | 0.207 | Mediator release inhibitor | 0.174 0.02 DBMET00391 | ||
| 0.241 | 0.057 | 0.246 | Peptidyltransferase inhibitor | 0.246 0.054 DBMET00391 | DBMET00391 | |
| 0.214 | 0.031 | 0.214 | 5 Hydroxytryptamine antagonist | 0.091 0.087 DBMET00391 | ||
| 0.187 | 0.007 | 0.187 | Acetylcholine M4 receptor antagonist | 0.11 0.022 DBMET00391 | ||
| 0.297 | 0.118 | 0.445 | Antiobesity | 0.445 0.051 DBMET00391 | DBMET00391 | |
| 0.187 | 0.02 | 0.187 | Calcium channel (voltage-sensitive) blocker | 0.17 0.025 DBMET00391 | ||
| 0.194 | 0.028 | 0.194 | Cholesterol synthesis inhibitor | 0.173 0.034 DBMET00391 | ||
| 0.222 | 0.057 | 0.222 | Neurotrophic factor enhancer | 0.174 0.105 DBMET00391 | ||
| 0.169 | 0.005 | 0.169 | Oleamide hydrolase inhibitor | 0.089 0.011 DBMET00391 | ||
| 0.184 | 0.02 | 0.184 | Alpha 2 adrenoreceptor antagonist | |||
| 0.272 | 0.112 | 0.272 | Vasodilator, coronary | 0.244 0.14 DBMET00391 | ||
| 0.228 | 0.075 | 0.228 | Cyclic AMP phosphodiesterase inhibitor | 0.178 0.113 DBMET00391 | ||
| 0.182 | 0.03 | 0.182 | Alpha adrenoreceptor antagonist | |||
| 0.178 | 0.027 | 0.178 | Adenylate cyclase stimulant | 0.161 0.047 DBMET00391 | ||
| 0.269 | 0.125 | 0.269 | Calcium channel activator | 0.241 0.158 DBMET00391 | ||
| 0.235 | 0.092 | 0.235 | Cardiotonic | |||
| 0.166 | 0.026 | 0.166 | Alpha 1 adrenoreceptor antagonist | |||
| 0.208 | 0.07 | 0.208 | Anesthetic general | 0.15 0.114 DBMET00391 | ||
| 0.24 | 0.107 | 0.249 | Lipoxygenase inhibitor | 0.249 0.101 DBMET00391 | DBMET00391 | |
| 0.324 | 0.193 | 0.461 | Antiinflammatory | 0.461 0.105 DBMET00391 | DBMET00391 | |
| 0.15 | 0.024 | 0.15 | Alpha 1a adrenoreceptor antagonist | |||
| 0.157 | 0.031 | 0.157 | Nav1.1 sodium channel blocker | 0.095 0.072 DBMET00391 | ||
| 0.206 | 0.081 | 0.42 | Interleukin antagonist | 0.42 0.028 DBMET00391 | DBMET00391 | |
| 0.16 | 0.037 | 0.16 | Pregnane X receptor agonist | |||
| 0.154 | 0.036 | 0.182 | Sphingosine 1-phosphate receptor 2 antagonist | 0.182 0.014 DBMET00391 | DBMET00391 | |
| 0.13 | 0.014 | 0.13 | Leukotriene synthesis inhibitor | 0.109 0.021 DBMET00391 | ||
| 0.218 | 0.104 | 0.227 | Interleukin agonist | 0.227 0.097 DBMET00391 | DBMET00391 | |
| 0.117 | 0.008 | 0.117 | Dopamine D5 antagonist | 0.068 0.015 DBMET00391 | ||
| 0.191 | 0.083 | 0.191 | Amyloid beta aggregation inhibitor | 0.129 0.126 DBMET00391 | ||
| 0.145 | 0.04 | 0.145 | Ferrochelatase inhibitor | 0.138 0.043 DBMET00391 | ||
| 0.123 | 0.019 | 0.123 | Dopamine D3 antagonist | |||
| 0.105 | 0.004 | 0.105 | Beta 2 adrenoreceptor agonist | 0.083 0.008 DBMET00391 | ||
| 0.131 | 0.032 | 0.131 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.149 | 0.053 | 0.149 | Farnesoid X receptor antagonist | 0.13 0.083 DBMET00391 | ||
| 0.146 | 0.054 | 0.146 | Ca2+-transporting ATPase inhibitor | 0.142 0.065 DBMET00391 | ||
| 0.164 | 0.076 | 0.164 | Sigma receptor agonist | 0.118 0.117 DBMET00391 | ||
| 0.105 | 0.024 | 0.105 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.101 | 0.021 | 0.101 | CC chemokine 5 receptor agonist | |||
| 0.226 | 0.147 | 0.226 | Antithrombotic | 0.218 0.156 DBMET00391 | ||
| 0.112 | 0.033 | 0.112 | Neuropeptide Y antagonist | |||
| 0.126 | 0.047 | 0.126 | 5-Lipoxygenase inhibitor | |||
| 0.107 | 0.03 | 0.107 | Dopamine D2 antagonist | |||
| 0.094 | 0.02 | 0.094 | Adrenaline uptake inhibitor | 0.06 0.045 DBMET00391 | ||
| 0.103 | 0.033 | 0.103 | CC chemokine receptor antagonist | 0.075 0.056 DBMET00391 | ||
| 0.251 | 0.182 | 0.251 | Analgesic | |||
| 0.264 | 0.197 | 0.415 | Cyclophilin D inhibitor | 0.415 0.083 DBMET00391 | DBMET00391 | |
| 0.108 | 0.044 | 0.108 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.118 | 0.057 | 0.118 | Nav1.5 sodium channel blocker | |||
| 0.125 | 0.064 | 0.125 | Adenylate cyclase inhibitor | |||
| 0.063 | 0.005 | 0.063 | Prostaglandin D2 agonist | 0.062 0.005 DBMET00391 | ||
| 0.11 | 0.053 | 0.11 | Gastric antisecretory | |||
| 0.108 | 0.052 | 0.108 | Anabolic | 0.098 0.066 DBMET00391 | ||
| 0.129 | 0.073 | 0.129 | Nav1.2 sodium channel blocker | |||
| 0.096 | 0.04 | 0.096 | Dopamine antagonist | |||
| 0.165 | 0.111 | 0.195 | Platelet aggregation inhibitor | 0.195 0.084 DBMET00391 | DBMET00391 | |
| 0.102 | 0.048 | 0.102 | Toll-Like receptor 3 antagonist | |||
| 0.07 | 0.018 | 0.07 | CC chemokine 5 receptor antagonist | 0.059 0.027 DBMET00391 | ||
| 0.078 | 0.028 | 0.083 | Prostaglandin EP2 antagonist | 0.083 0.025 DBMET00391 | DBMET00391 | |
| 0.068 | 0.018 | 0.068 | Alpha-mannosidase inhibitor | 0.059 0.028 DBMET00391 | ||
| 0.058 | 0.009 | 0.058 | Beta adrenoreceptor agonist | 0.048 0.021 DBMET00391 | ||
| 0.171 | 0.122 | 0.171 | Aldehyde oxidase inhibitor | 0.152 0.137 DBMET00391 | ||
| 0.064 | 0.015 | 0.064 | Mannosidase inhibitor | 0.053 0.022 DBMET00391 | ||
| 0.058 | 0.009 | 0.058 | Sigma 1 receptor antagonist | |||
| 0.194 | 0.146 | 0.209 | Tyrosine 3 hydroxylase inhibitor | 0.209 0.119 DBMET00391 | DBMET00391 | |
| 0.212 | 0.166 | 0.212 | Ca(v)3.3 blocker | |||
| 0.051 | 0.006 | 0.051 | Ceramide glucosyltransferase inhibitor | 0.04 0.017 DBMET00391 | ||
| 0.093 | 0.052 | 0.093 | Ornithine decarboxylase inhibitor | 0.08 0.067 DBMET00391 | ||
| 0.05 | 0.01 | 0.05 | Prostaglandin agonist | 0.047 0.011 DBMET00391 | ||
| 0.117 | 0.077 | 0.117 | Nav1.3 sodium channel blocker | |||
| 0.045 | 0.007 | 0.045 | Prostaglandin EP2 agonist | 0.041 0.008 DBMET00391 | ||
| 0.072 | 0.034 | 0.072 | DNA gyrase inhibitor | 0.058 0.051 DBMET00391 | ||
| 0.047 | 0.01 | 0.047 | Sigma 2 receptor antagonist | |||
| 0.132 | 0.097 | 0.161 | Sphingosine 1-phosphate receptor 5 antagonist | 0.161 0.045 DBMET00391 | DBMET00391 | |
| 0.157 | 0.123 | 0.157 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.047 | 0.018 | 0.047 | GABA uptake inhibitor | 0.042 0.023 DBMET00391 | ||
| 0.135 | 0.106 | 0.135 | Arachidonic acid antagonist | |||
| 0.06 | 0.032 | 0.06 | Pregnane X receptor antagonist | |||
| 0.067 | 0.04 | 0.067 | Interferon inducer | |||
| 0.093 | 0.066 | 0.093 | Bile acid receptor antagonist | |||
| 0.035 | 0.009 | 0.035 | Prostaglandin E2 agonist | 0.032 0.01 DBMET00391 | ||
| 0.132 | 0.107 | 0.132 | Interferon gamma antagonist | |||
| 0.078 | 0.055 | 0.078 | Interferon agonist | |||
| 0.204 | 0.182 | 0.245 | Interleukin 2 agonist | 0.245 0.125 DBMET00391 | DBMET00391 | |
| 0.052 | 0.03 | 0.052 | Squalene epoxidase inhibitor | |||
| 0.083 | 0.062 | 0.083 | Vanilloid agonist | |||
| 0.116 | 0.102 | 0.116 | Nav1.6 sodium channel blocker | |||
| 0.094 | 0.08 | 0.094 | Alpha 2b adrenoreceptor antagonist | |||
| 0.068 | 0.055 | 0.068 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.062 | 0.051 | 0.062 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.037 | 0.027 | 0.037 | Delayed rectifier potassium channel blocker | |||
| 0.054 | 0.044 | 0.054 | Adenine nucleotide translocase inhibitor | |||
| 0.063 | 0.056 | 0.063 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.012 | 0.006 | 0.012 | Thromboxane agonist | 0.012 0.006 DBMET00391 | ||
| 0.073 | 0.067 | 0.073 | Viral attachment inhibitor | |||
| 0.04 | 0.038 | 0.04 | 5 Hydroxytryptamine 1A agonist | |||
| 0.075 | 0.086 | 0.086 | HIV-1 integrase (Overall Integration) inhibitor | 0.086 0.07 DBMET00391 | DBMET00391 | |
| 0.019 | 0.031 | 0.06 | Leukotriene B4 receptor 1 antagonist | 0.06 0.005 DBMET00391 | DBMET00391 | |
| 0.137 | 0.16 | 0.226 | Platelet antagonist | 0.226 0.084 DBMET00391 | DBMET00391 | |
| 0.06 | 0.083 | 0.078 | Peroxisome proliferator-activated receptor gamma antagonist | 0.078 0.036 DBMET00391 | DBMET00391 | |
| 0.184 | 0.211 | 0.256 | Sodium/bile acid cotransporter inhibitor | 0.256 0.122 DBMET00391 | DBMET00391 | |
| 0.04 | 0.07 | 0.062 | Leukotriene B4 antagonist | 0.062 0.026 DBMET00391 | DBMET00391 | |
| 0.128 | 0.176 | 0.201 | Antiamyloidogenic | 0.201 0.099 DBMET00391 | DBMET00391 | |
| 0.039 | 0.1 | 0.074 | Leukotriene antagonist | 0.074 0.036 DBMET00391 | DBMET00391 | |
| 0.054 | 0.119 | 0.065 | MDM2 inhibitor | 0.065 0.054 DBMET00391 | DBMET00391 | |
| 0.111 | 0.193 | 0.14 | Lipocortins synthesis antagonist | 0.14 0.121 DBMET00391 | DBMET00391 | |
| 0.009 | 0.102 | 0.038 | Leukotriene B4 receptor 2 antagonist | 0.038 0.005 DBMET00391 | DBMET00391 | |
| 0.052 | 0.151 | 0.076 | Sphingosine 1-phosphate receptor antagonist | 0.076 0.055 DBMET00391 | DBMET00391 | |
| 0.018 | 0.788 | 0.201 | Interleukin 2 antagonist | 0.201 0.008 DBMET00391 | DBMET00391 | |
| 0.005 | 0.911 | 0.136 | Amyloid beta precursor protein antagonist | 0.136 0.118 DBMET00391 | DBMET00391 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |